Retrospective long-term follow-up in patients with chronic palmoplantar dermatoses after good response to bath PUVA therapy.
BACKGROUND
Numerous studies have confirmed the short-term effectiveness of 8-methoxypsoralen bath PUVA therapy in patients with chronic palmoplantar dermatoses; however, little is known about long-term results.


METHODS
In this retrospective study we examined the long-term results in 79 patients (mean age: 48 years) with chronic palmoplantar dermatoses who were treated with bath PUVA three times a week over an 8-year period. A good clinical response (a reduction of more than 50% of the skin lesions) occurred after a mean of 23 treatments and a mean cumulative UVA dose of 39 J/cm(2) in 51 patients (65%). In 2007 a questionnaire was sent to these 51 patients to assess the long-term outcome.


RESULTS
With bath PUVA treatment, the best results were found in patients with hyperkeratotic eczema (17/22; 77% good clinical response) followed by patients with palmoplantar psoriasis (26/41; 63%) and patients with dyshidrotic eczema (8/16; 50%). Thirty-four patients (67%) answered the questionnaire after a mean follow-up interval of 4.3 years (10-87 months). Among these patients, 36% reported an improved course of disease after PUVA therapy with reduced frequency and/or intensity of the skin rash, and 29% of patients reported continued complete clearance. 79% of our patients reported a long-term reduction in the use of topical corticosteroids during the follow-up period (mean: 4.3 years). In addition, 67% of patients reported a lasting improvement in quality of life.


CONCLUSIONS
These data show that bath PUVA may have a long-term, beneficial influence on the course of disease in a majority of patients with recalcitrant chronic palmoplantar dermatoses.
Research Unit for Photodermatology, Department of Dermatology and Venereology, Medical University of Graz, Austria.
Agnes
A
Bretterklieber
Franz J
FJ
Legat
Peter
P
Wolf
Angelika
A
Hofer
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001494:Baths / Q000706:statistics & numerical data*; D002908:Chronic Disease; D003131:Combined Modality Therapy / Q000706:statistics & numerical data; D011146:Eczema, Dyshidrotic / Q000188:drug therapy* / Q000453:epidemiology* / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D011564:Furocoumarins / Q000627:therapeutic use; D005858:Germany / Q000453:epidemiology; D006801:Humans; D007645:Keratoderma, Palmoplantar / Q000188:drug therapy* / Q000453:epidemiology* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011701:PUVA Therapy; D015995:Prevalence; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use; D012189:Retrospective Studies; D012307:Risk Factors; D016896:Treatment Outcome
D011564:Furocoumarins; D011838:Radiation-Sensitizing Agents; C051039:8-methylpsoralen